Evidence map›Paper›PMID 35276485›Full record

ArticleVirology2022

Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.

Taotao Mi, Tiantian Wang, Huifang Xu, Peng Sun, Xuchen Hou, Xinwei Zhang, Qian Ke, Jiawen Liu, Shengwei Hu, Jun Wu and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Taotao MiCollege of Life Sciences, Shihezi University, Shihezi, Xinjiang, 832003, China; Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Tiantian WangDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Huifang XuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Peng SunDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Xuchen HouDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Xinwei ZhangDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China; College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi, 712100, China.
Qian KeDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China; Institute of Physical Science and Information Technology, Anhui University, Hefei, 230000, China.
Jiawen LiuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China.
Shengwei HuCollege of Life Sciences, Shihezi University, Shihezi, Xinjiang, 832003, China. Electronic address: hushengwei@163.com.
Jun WuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China. Electronic address: junwu1969@163.com.
Bo LiuDepartment of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing, 100071, China. Electronic address: liubo7095173@163.com.
Beijing Microelectronics Technology Institute · CNShihezi University · CNNorth West Agriculture and Forestry University · CNUniversity of Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kappa (B.1.617.1) variant represented the main variant of concern (VOC) for the epidemic in India in May 2021. We have previously established a technology platform for rapidly preparing SARS-CoV-2 receptor-binding domain (RBD) candidate vaccines based on glycoengineered Pichia pastoris. Our previous study revealed that the wild-type RBD (WT-RBD) formulated with aluminum hydroxide and CpG 2006 adjuvant effectively induces neutralizing antibodies in BALB/c mice. In the present study, a glycoengineered P. pastoris expression system was used to prepare recombinant kappa-RBD candidate vaccine. Kappa-RBD formulated with CpG and alum induced BALB/c mice to produce a potent antigen-specific antibody response and neutralizing antibody titers against pseudoviruses of SARS-CoV-2 kappa, delta, lambda, beta, and omicron variants and WT. Therefore, the recombinant kappa-RBD vaccine has sufficient potency to be a promising COVID-19 vaccine candidate.

Indexed as

COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansMiceMice, Inbred BALB CReceptors, Opioid, kappaSaccharomycetalesSpike Glycoprotein, CoronavirusVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesReceptors, Opioid, kappaSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SyntheticReceptor-binding domain (RBD)SARS-CoV-2 kappaVaccineYeast

Identifiers

PMID35276485
PMCPMC8898337
OpenAlexW4220771681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.